|
Sep 27
|
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
|
|
Sep 27
|
Top Midday Stories: Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug; Novo Nordisk Shares Drop After Analyst's Sales Concerns
|
|
Sep 27
|
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
|
|
Sep 27
|
FDA approves new Bristol Myers Squibb schizophrenia drug
|
|
Sep 27
|
These Stocks Are Moving the Most Today
|
|
Sep 27
|
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
|
|
Sep 27
|
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
|
|
Sep 27
|
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
|
|
Sep 27
|
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
|
|
Sep 27
|
Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug
|
|
Sep 27
|
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Breaks Out
|
|
Sep 27
|
Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug
|
|
Sep 27
|
Bristol-Myers Squibb stock gains on FDA approval of schizophrenia treatment
|
|
Sep 27
|
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
|
|
Sep 27
|
Stock Market Today: Dow ends at record high on muted PCE inflation data
|
|
Sep 11
|
Prodrugs and patents: Enhancing therapy adherence and reducing side effects
|
|
Sep 9
|
Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
|
|
Sep 8
|
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
|
|
Sep 6
|
Implied Volatility Surging for Bristol-Myers (BMY) Stock Options
|
|
Sep 6
|
Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last?
|